Clinical Trial

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

Study acronym: VAC093
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and children aged 5-17 months in Burkina Faso.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-02; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT06958198
Lead Sponsor University of Oxford
Collaborators: Institut de Recherche en Sciences de la Sante, Burkina Faso, European and Developing Countries Clinical Trials Partnership (EDCTP), Wellcome Trust, European Vaccine Initiative, Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)
Conditions Malaria,Falciparum
Enrollment 56 participants
Start Date 2025-09-15
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-11